Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Up 15.8% in November

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the recipient of a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 11,000 shares, a growth of 15.8% from the November 15th total of 9,500 shares. Currently, 0.2% of the company’s stock are sold short. Based on an average daily trading volume, of 25,400 shares, the days-to-cover ratio is currently 0.4 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Aprea Therapeutics in a report on Monday, November 18th.

Insiders Place Their Bets

In other news, Director Marc Duey sold 6,462 shares of the business’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $4.58, for a total value of $29,595.96. Following the sale, the director now owns 233,651 shares in the company, valued at approximately $1,070,121.58. The trade was a 2.69 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bernd R. Seizinger purchased 10,000 shares of Aprea Therapeutics stock in a transaction that occurred on Friday, October 11th. The shares were bought at an average price of $2.68 per share, for a total transaction of $26,800.00. Following the transaction, the director now owns 44,730 shares in the company, valued at $119,876.40. This represents a 28.79 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 42,290 shares of company stock valued at $165,096 over the last three months. 12.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. Dimensional Fund Advisors LP purchased a new stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned approximately 0.20% of Aprea Therapeutics as of its most recent filing with the Securities & Exchange Commission. 34.19% of the stock is owned by hedge funds and other institutional investors.

Aprea Therapeutics Price Performance

NASDAQ:APRE traded down $0.32 during trading hours on Friday, reaching $3.20. 25,108 shares of the company were exchanged, compared to its average volume of 20,368. Aprea Therapeutics has a 1-year low of $2.15 and a 1-year high of $8.85. The company has a market capitalization of $17.36 million, a P/E ratio of -1.13 and a beta of 0.88. The business has a 50 day moving average of $3.41 and a 200 day moving average of $3.60.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.11. The business had revenue of $0.35 million for the quarter, compared to analyst estimates of $0.45 million. Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%. As a group, equities research analysts anticipate that Aprea Therapeutics will post -2.55 earnings per share for the current fiscal year.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.